Zhan-Dong Hu1, Ying Jiang2, Hong-Mei Sun3, Jing-Wen Wang1, Li-Li Zhai1, Zhi-Qi Yin1, Jun Yan1. 1. Department of Pathology in Tianjin First Central Hospital, Number 24, Convalescent Road, Nankai, Tianjin 300192, China. 2. Department of Clinical Laboratory in Tianjin First Central Hospital, Number 24, Convalescent Road, Nankai, Tianjin 300192, China. 3. Department of Out-Patient in Tianjin First Central Hospital, Number 24, Convalescent Road, Nankai, Tianjin 300192, China.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) lacks effective treatments and has a poor prognosis. Therefore it is needed to develop more effective drug targets. Kinesin family member 11 (KIF11) has been reported to affect the progression of several cancers, and its high expression associates with the prognosis of patients. However, the relevant mechanisms of KIF11 in HCC progression have not been studied. METHOD: Through the cancer genome atlas (TCGA) database and immunohistochemical (IHC) staining of patients' specimens, we determined that KIF11 was highly expressed in HCC tissues and associated with prognosis. We established a KIF11 stably depleted hepatoma cell line, through cell-cloning experiments and cell counting kit-8 (CCK-8) assays to detect the effects on proliferation in vitro. The role of KIF11 in promoting cell proliferation was verified in mice. RESULT: The expression of KIF11 was negatively correlated with the overall survival (OS) and disease-free survival (DFS) and positively correlated with tumor size of HCC patients. KIF11 depletion inhibits cell proliferation and tumor growth in vitro and in vivo. Conclusion. KIF11 can be used as a positive correlation marker for HCC prognosis and served as a potential therapeutic target.
BACKGROUND: Hepatocellular carcinoma (HCC) lacks effective treatments and has a poor prognosis. Therefore it is needed to develop more effective drug targets. Kinesin family member 11 (KIF11) has been reported to affect the progression of several cancers, and its high expression associates with the prognosis of patients. However, the relevant mechanisms of KIF11 in HCC progression have not been studied. METHOD: Through the cancer genome atlas (TCGA) database and immunohistochemical (IHC) staining of patients' specimens, we determined that KIF11 was highly expressed in HCC tissues and associated with prognosis. We established a KIF11 stably depleted hepatoma cell line, through cell-cloning experiments and cell counting kit-8 (CCK-8) assays to detect the effects on proliferation in vitro. The role of KIF11 in promoting cell proliferation was verified in mice. RESULT: The expression of KIF11 was negatively correlated with the overall survival (OS) and disease-free survival (DFS) and positively correlated with tumor size of HCC patients. KIF11 depletion inhibits cell proliferation and tumor growth in vitro and in vivo. Conclusion. KIF11 can be used as a positive correlation marker for HCC prognosis and served as a potential therapeutic target.
Authors: Carolyn J Lawrence; R Kelly Dawe; Karen R Christie; Don W Cleveland; Scott C Dawson; Sharyn A Endow; Lawrence S B Goldstein; Holly V Goodson; Nobutaka Hirokawa; Jonathon Howard; Russell L Malmberg; J Richard McIntosh; Harukata Miki; Timothy J Mitchison; Yasushi Okada; Anireddy S N Reddy; William M Saxton; Manfred Schliwa; Jonathan M Scholey; Ronald D Vale; Claire E Walczak; Linda Wordeman Journal: J Cell Biol Date: 2004-10-11 Impact factor: 10.539
Authors: Christine Haider; Julia Hnat; Roland Wagner; Heidemarie Huber; Gerald Timelthaler; Markus Grubinger; Cédric Coulouarn; Wolfgang Schreiner; Karin Schlangen; Wolfgang Sieghart; Markus Peck-Radosavljevic; Wolfgang Mikulits Journal: Hepatology Date: 2018-12-20 Impact factor: 17.425